Skip to main content
. 2021 Sep 10;7(37):eabg5016. doi: 10.1126/sciadv.abg5016

Fig. 4. Use of salt as an adjuvant in combination with suboptimal dose of anti-PD1–neutralizing antibody.

Fig. 4.

(A) Schematic methodology and (B) tumor progression for combinatorial therapy involving salt and suboptimal dose of anti-PD1–neutralizing antibody and (C) its survival curve and (D) the subsequent profiling for PD1 expression on NK cells. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (Student’s t test or one-way ANOVA).